MedPath

The combined therapy with Olmesartan and Azelnidipin in the hypertensive patients with sleep apnea syndrome (SAS)

Not Applicable
Conditions
Sleep Apnea Syndrome
Registration Number
JPRN-UMIN000007171
Lead Sponsor
Department of Internal Medicine, Graduate School of Medical Science, Kanazawa University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

1) The patient who is taking azelnidipine or amlodipine 2) The patient who has critical liver disease. (AST or ALT is 100 or more IU/L) 3) The patient who has a critical renal disease (the patient under dialysis enforcement is included). (more than BUN 25mg/dL or more than serum creatinine 2.0mg/dL) 4) Pregnant or lactating women

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Blood pressure(Clinic BP,Home BP)
Secondary Outcome Measures
NameTimeMethod
PSG, AHI, noradrenalin, cortisol, Plasma aldosterone concentration, Plasma renin activity, ACTH, BNP,blood sugar level, renal function(the very-small-quantity albumin in urine, albuminuria, eGFR), Salt intake,HOMA-R, PAI-1, adiponectin
© Copyright 2025. All Rights Reserved by MedPath